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When positron emission tomography (PET) scanning was
introduced at the end of the 1970s, its technical characteristics
and biological potential aroused immediate interest. The available
tracers at time (isotopes of oxygen, nitrogen, and carbon) made it
possible to study blood flow, regional oxygen consumption, the
main metabolic pathways and ligand–receptor interactions in the
brain, heart and other major organs, without physiological
perturbations. Although the promise of the technique was fulfilled,
its use has not developed as rapidly as expected.
Positron emission tomography scanning was initially used to
study the brain and the heart, but today it is used mainly in
oncology. This is partly due to technological developments that
allow whole-body examinations. There is also a growing number of
publications suggesting that this technique is useful in the
management of many cancers, from initial staging to post-
therapeutic follow-up.
The tracer generally used is 2-[
18F]fluoro-2-deoxy-D-glucose
(FDG), which is a glucose analogue that competes with glucose at
the level of transmembrane transporters. Although other tracers
have been proposed ([
11C]methionine, [
11C]tyrosine and [
11C]thy-
midine), their use has not yet been validated, and the carbon-11
label is a limiting factor for extensive routine use. Nearly 70 years
ago, Warburg demonstrated an increase in glycolytic activity in
cancer cells, and this is the basis for use of FDG in oncology.
Briefly, in most cancers, neoplastic transformation induces an
increase in glucose transporters (particularly GLUT1) and in the
activity of glycolytic enzymes (particularly hexokinase). These
changes are responsible for an increase in glycolytic activity in
cancer cells, under both aerobic and anaerobic conditions. The
glycolytic activity is related to the viable tumour cell mass, as the
increase in glucose transport reflects cell proliferation. Accumula-
tion of glucose is not specific to malignant tumours but can also be
increased in benign tumours and in inflammatory diseases, such as
sarcoidosis and granulomatosis.
In 2001, there were only four operational PET scanners in France,
dedicated to clinical use. Since then, the Government has authorised
the installation of about 40 sites, with a final objective of 60 PET
scanners so as to provide adequate access throughout the country.
The most important question about the use of PET scanning in
oncology is: ‘What is its usefulness in comparison with other
imaging techniques?’ The answer requires not only comparing the
performance of PET scanning with that of other imaging
techniques, but also evaluating the impact of use of PET on the
management of patients with cancer. Although, many studies are
under way, only a few publications specifically addressing the
question are available.
As with most medical imaging techniques, the clinical use of PET
has developed before its efficacy and efficiency have been clearly
demonstrated. The fields of application of PET scanning are evolving
continuously with new research findings. However, the rapid pace of
technological improvements to PET scanning results in an ever
increasing list of applications, but this also prevents the accumula-
tion of convincing data for evaluation. In this context, it was decided
that clinical practice guidelines were needed to define the potential
and recognised indications for FDG-PET scanning in oncology.
OBJECTIVES
The objective was to review the available scientific data and to
develop the Standards, Options, and Recommendations (SORs) for
the role of and indications for FDG-PET scanning in oncology. The
main steps in patient care that were studied were diagnosis of the
primary disease, initial and secondary metastatic assessment,
evaluation of treatment response, and detection of recurrent
disease. The recommendations made relate to the primary cancer
sites defined as priorities on the basis of the available scientific
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www.bjcancer.comdata: cancers of lung and pleural, melanoma, gynaecological
cancers, gastrointestinal cancers, head-and-neck cancers, urologi-
cal cancers, lymphomas, soft-tissue and bone sarcomas, and
cancers of the thyroid, and also carcinomas of unknown primary
site. For some cancer sites, the working group considered that an
evaluation was either not timely or that the available data were
inadequate. These topics, in particular cerebral tumours and
childhood cancers, will be addressed when these recommendations
are updated.
METHODS
The details of the methodology have been published previously
(Fervers et al, 2001). For this particular SOR, a multidisciplinary
group of experts was set up by the French National Federation of
Cancer Centres (FNCLCC) and the French Society for Biophysics
and Nuclear Medicine (Socie ´te ´ Franc¸aise de Biophysique et
Me ´decine Nuclear, SFBMN) to critically appraise the available
evidence on the role of and indications for FDG-PET scanning in
oncology.
Literature searches were performed for each cancer site in
Medline
s, from January 1996 to November 2001, and in the
Cochrane
s Library, Issue 3, 1999. The Cancerlit
s database and the
proceedings from American Society of Clinical Oncology confer-
ences were also searched. The search excluded articles in languages
other than English and French, as well as in vitro and animal
studies. Studies in which tracers other than FDG were used were
not specifically sought, although studies comparing FDG with
other tracers were included for certain cancer sites, when they
provided data for the relevant outcomes. The review met with a
recurrent difficulty: multiple publication in different journals of
the same study, with an increasing number of patients, and
sometimes with the authors in a different order. In this situation,
only the last publication, including the largest number of patients,
was retained for this report.
The literature search was complemented with personal refer-
ences supplied by the experts. In certain chapters, references
published after November 2001 were added when the working
group considered it necessary, especially when the new references
had an impact on the definition of a standard or an option. The
data analysis also included three reports of evaluations and
recommendations for FDG-PET scanning (Adams et al, 1999;
Robert and Milne, 1999; AETMIS, Agence d’e ´valuation des
technologies et des modes d’intervention en sante ´, 2001) and the
report of a German consensus conference (Reske and Kotzerke,
2001).
The working group selected and critically appraised pertinent
references and then proposed the ‘Standards’, ‘Options’, and
‘Recommendations’ for the role of and indications for FDG-PET
scanning in oncology, based on either the best available evidence
or expert agreement.
‘Standards’ identify clinical situations for which there exist
strong indications or contraindications for a particular FDG-PET
application and ‘Options’ identify situations for which there are
several alternatives, none of which have shown clear superiority
over the others (Table 1). In any SOR, there can be several
‘Options’ for a given clinical situation. ‘Recommendations’ enable
the ‘Options’ to be weighted according to the available evidence.
Several FDG-PET applications can be recommended for the same
clinical situation, so that clinicians can make a choice according to
specific clinical parameters, for example, local circumstances,
skills, equipment, resources, and patient preferences. Adapting the
SORs to a local situation is possible if the reason for the choice is
sufficiently transparent and this is crucial for successful imple-
mentation. Inclusion of patients in clinical trials is an appropriate
form of patient management in oncology and is recommended
frequently within the SORs, particularly in situations where
evidence is too weak to support a particular FDG-PET application.
The type of evidence underlying any ‘Standard’, ‘Option’, or
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgment is made
according to professional experience and consensus of the working
group (‘expert agreement’).
In this particular situation, that is, a diagnostic test, it is
sometimes difficult to classify levels of evidence. In addition, PET
scanning is an emerging technique, for which many indications are
Table 1 Definition of Standards, Options and Recommendations
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by unanimous decision based on the best available
evidence
Options Procedures or treatments that are considered to be of benefit, inappropriate or harmful by a majority, based on the best available evidence.
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g. survival, toxicity) with an indication of the level
of evidence
Table 2 Definition of level of evidence
Level A
There exist a high-standard meta-analysis or several high-standard randomised clinical trial which give consistent results
Level B
There exists good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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Summary of Standards, Options and Recommendations by indication
Indications in French
Product licence 1998
Standard Option Further trials required Situations where PET
scanning is not indicated
Cancers of the lung and pleura
Lung Differential diagnosis of
pulmonary masses
Diagnosis of malignancy in a
solitary pulmonary lesion larger
than 1cm, suspicious of
malignancy on initial imaging
(level of evidence: A)
Diagnosis of malignancy in a
pulmonary lesion less than
1cm (level of evidence: B2)
Evaluation of response to
anticancer treatment
(level of evidence: D)
Screen for cerebral metastases
(standard, expert agreement)
Staging and assessment
of recurrent disease
Assessment of locoregional
involvement and metastatic
screen (particularly adrenal
gland) (level of evidence: A)
Differential diagnosis of
recurrence or residual disease
from post-treatment fibrosis
(level of evidence: B2)
Optimisation of radiotherapy
fields (in combination with
CT scan) (level of evidence: B2)
Pleura Diagnosis of malignancy in pleural
lesions (level of evidence: B2)
Local and distance metastatic
screening in patients with
malignant pleural lesions
Contribution of determination
of a biopsy site
(level of evidence: D)
Mediastinum PET scanning is not indicated
outside the setting of a
clinical trial (standard)
Melanoma
Cutaneous
melanoma
Initial metastatic screen Initial metastatic screen in patients
with melanoma at high risk of
metastases (Stage III AJCC)
(level of evidence: B2)
Screen for recurrence as
part of follow-up
(level of evidence: C)
Screen for nodal
micrometastases
(level of evidence: B1)
Assessment of operability in
metastases thought to be
solitary (level of evidence: B2)
Other melanomas PET scanning is not indicated
outside the setting of a
clinical trial (standard)
Gynaecological malignancies
Breast cancer Locoregional and distant metastatic
screen for patients with invasive
tumours (level of evidence: B2)
Evaluation of response to
neoadjuvant chemotherapy
(level of evidence: D)
Diagnosis of malignant breast
tumours (standard, level of
evidence: B2)
Suspicion of local or metastatic
recurrence (level of evidence: B2)
Detection of nodal
micrometastases standard,
(level of evidence: B2)
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CTable 3 Continued
Summary of Standards, Options and Recommendations by indication
Indications in French
Product licence 1998
Standard Option Further trials required Situations where PET
scanning is not indicated
Ovarian cancer Suspicion of local or
metastatic recurrence
(level of evidence: C)
Uterine cancer Assessment of nodal involvement in
patients with cancer of the cervix
(level of evidence: B2)
Not indicated in patients with
cancer of the endometrium
or vagina outside the setting
of a clinical trial (standard)
Gastrointestinal cancers
Cancer of the
oesophagus
Pretreatment evaluation of nodal
and metastatic status to complement
scans and endoscopic ultrasound
(level of evidence: B2)
Gastric
carcinoma
No indication outside the
setting of a clinical trial
(recommendation,
expert agreement)
Colorectal cancer Assessment of operability of
recurrent disease and metastases
Diagnosis of recurrence in patients with
confirmed elevation of serum carcinoembryonic
antigen (level of evidence: B2)
Preoperative initial staging
(level of evidence: C)
Preoperative staging of local and
metastatic recurrence
(level of evidence: B2)
Pancreatic
cancer
Differential diagnosis and staging in
patients with normal serum
glucose (level of evidence: B2)
Hepatic
carcinoma
Differential diagnosis of hepatic
metastases, cholangiocarcinomas
and benign tumours in patients
with a solitary hepatic lesion
(expert agreement)
Metastatic screen for patients
with hepatocellular carcinoma
(level of evidence: B2)
Early diagnosis of a
cholangiocarcinoma in patients
with sclerosing cholangitis
(level of evidence: C)
Neuro-endocrine
tumours
Diagnosis and staging only in
patients with a normal octreotide
scan (expert agreement)
No indication for PET scanning
as first-line imaging (level of
evidence: B2)
Cancer of the head and neck
Initial metastatic screen for
patients with cancer of the
pharynx
Metastatic screen for patients
with untreated cancers of the
head and neck (level of
evidence: B2)
Differential diagnosis
between benign and
malignant tumours when a
biopsy has not been conclusive
(level of evidence: B2)
Early evaluation of the efficacy
of chemotherapy
(level of evidence: C)
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CCancers of the
head and neck
Diagnosis of recurrence (level
of evidence: B2)
Search for a second concurrent
malignancy (level of evidence: B2)
Search for a primary tumour in
patients with metastatic cervical
lymphadenopathy with unknown
primary site (level of evidence: C)
Cancers of the
salivary glands
No indication outside the setting
of a clinical trial (standard)
Lymphomas
Initial staging, follow-up for
early treatment and search
for residual disease
Initial metastatic screen and as a
complement to conventional
imaging in HD, high-grade
NHL and follicular lymphomas
(level of evidence: B2)
Early evaluation of response
to treatment (level of
evidence: D)
Diagnosis of residual disease
(level of evidence: B2
Sarcomas
Soft-tissue sarcomas Search for local recurrence
(level of evidence: B2)
To guide biopsy
(level of evidence: B2)
Osteosarcoma Characterisation of suspected
primary bone tumour
(level of evidence: C)
Urological cancers
Renal cell carcinoma Search of local recurrence or
distant metastases in patients
with symptoms
(level of evidence: C)
Diagnosis of a primary
renal cell carcinoma
(level of evidence: C)
Initial metastatic screen
(level of evidence: C)
Table 3 Continued
Summary of Standards, Options and Recommendations by indication
Indications in French
Product licence 1998
Standard Option Further trials required Situations where PET
scanning is not indicated
HD=Hodgkin’s disease; NHL=non-Hodgkin’s lymphoma.
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CProstate carcinoma Initial locoregional and
distant metastatic screen
(level of evidence: C)
Diagnosis of a primary prostate
cancer (standard, level of
evidence: B2)
Suspicion of local recurrence
(level of evidence: C)
Diagnosis of suspicious
abnormalities on bone scan
(level of evidence: D)
Testicular cancer Detection of malignancy in
post-treatment residual mass
(level of evidence: B2)
Initial metastatic screen
(level of evidence: C)
Diagnosis of a primary testicular
tumour (standard)
Search for recurrent disease in
patients with increased serum
concentrations of tumour
markers at follow-up
(Level of evidence: C)
Differential diagnosis between a
fibrous mass and a mature
teratoma (standard)
Bladder cancer No indication outside the
setting of a clinical trial
(standard)
Carcinoma of unknown primary site
Search for primary tumour in
patients with metastatic
cervical lymphadenopathy
(level of evidence: C)
Cancers of the thyroid
Well-differentiated
thyroid cancer
Suspicion of residual disease or
recurrence when standard imaging
results (including radioactive iodine
scans) are not conclusive
(level of evidence: B2)
Diagnosis of thyroid nodules
(standard, level of evidence: B2)
Medullary cancer of
the thyroid
Preoperative staging if further
surgery is indicated for
persistent or recurrent
disease (level of evidence: B2)
Table 3 Continued
Summary of Standards, Options and Recommendations by indication
Indications in French
Product licence 1998
Standard Option Further trials required Situations where PET
scanning is not indicated
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identify not only standards and options for protocols being
evaluated but also indications that require confirmation. The
standards are based on levels of evidence A or B and represent
indications for which the working group considered that PET
scanning is essential for the care of patients. The options are
usually based on a high level of evidence (B2), whereas the
indications that require confirmation are those for which
published data are scarce or insufficient (levels of evidence C, D,
and expert agreement). For certain indications, despite a low level
of evidence, the clinical usefulness of PET scanning was considered
by the working group to be high, thus the indication is classified as
an option (expert agreement).
The document containing the SORs was then reviewed by a
group of independent experts (see the Appendix) and after taking
into consideration their comments, the guidelines were validated
by the working group.
This English-language version is based on the summary
version, which was itself based on the French full text version
(Bourguet et al, 2003). The French full text and summary versions
are available on the FNCLCC web site (http://www.fnclcc.fr).
A working group has been set up to monitor new scientific data
on FDG-PET systematically. These clinical practice guidelines will
be updated when new evidence becomes available or if there is a
new consensus among the experts. In addition, patient-targeted
information is being developed by the SOR SAVOIR PATIENT
project, based on the specialist information (available late 2003).
The SORs for use of FDG-PET scanning in oncology are
summarised in Table 3.
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